168 related articles for article (PubMed ID: 24386644)
21. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
Yoshida S; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
[TBL] [Abstract][Full Text] [Related]
23. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
24. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
Fang Y; Xu J; Li Z; Yang Z; Xiong L; Jin Y; Wang Q; Xie S; Zhu W; Chang S
Bioorg Med Chem; 2018 Aug; 26(14):4080-4087. PubMed ID: 30100020
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
26. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
27. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601
[TBL] [Abstract][Full Text] [Related]
28. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
29. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
Matsumoto K; Yoshitomi T; Shimada T
Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
31. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
[TBL] [Abstract][Full Text] [Related]
32. β-Cell Inactivation of
Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
[TBL] [Abstract][Full Text] [Related]
33. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
34. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
[TBL] [Abstract][Full Text] [Related]
36. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
37. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
38. A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice.
Zheng C; Zhou W; Wang T; You P; Zhao Y; Yang Y; Wang X; Luo J; Chen Y; Liu M; Chen H
PLoS One; 2015; 10(7):e0134051. PubMed ID: 26208278
[TBL] [Abstract][Full Text] [Related]
39. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
Zhang SY; Li J; Xie X
Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
[TBL] [Abstract][Full Text] [Related]
40. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
